[1]伍 琳,廖诗语,陈嘉怡,等.多适应症药物医保支付的理论反思与实践走向 ——基于制度变迁视角[J].卫生经济研究,2024,41(06):10-15.
　WU Lin,LIAO Shiyu,CHEN Jiayi,et al.Theoretical Reflection and Practical Direction of Medical Insurance Payment for Multi-indication Drugs ——Based on the Perspective of Institutional Change[J].Journal Press of Health Economics Research,2024,41(06):10-15.
点击复制

多适应症药物医保支付的理论反思与实践走向
——基于制度变迁视角
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
41
期数:
2024年06期
页码:
10-15
栏目:
专题研究
出版日期:
2024-05-30

文章信息/Info

Title:
Theoretical Reflection and Practical Direction of Medical Insurance Payment for Multi-indication Drugs
——Based on the Perspective of Institutional Change
作者:
伍 琳1; 廖诗语1; 陈嘉怡1; 夏静琪1; 陈永法1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
WU Lin;  LIAO Shiyu;  CHEN Jiayi;  XIA Jingqi;  CHEN Yongfa
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
多适应症药物; 制度变迁; 价值; 真实世界数据
Keywords:
multi-indication drugs;  system change;  value;  real-world data
分类号:
R19
文献标志码:
A
摘要:
欧洲国家经验表明，实施多适应症药物支付（MIP）需要有三个方面的支撑条件。由于政策创新空间受限，且资源基础薄弱，当前我国实施MIP的难度较大。但随着社会经济形势变化，实施MIP的需求和条件基础也会不断变化，建议从公共价值创造、制度风险分担、实践效果追踪三个层面，推动我国多适应症药物支付制度变革。
Abstract:
The experience of European countries shows that the implementation of multi-indication pricing(MIP) requires three supporting conditions. Due to the limited space for policy innovation and the weak resource base, it is currently difficult to implement MIP in China. However, as the socio-economic situation changes, the needs and condition for implementing MIP will also change. It is recommended to promote the change of MIP payment system in China from the three aspects of public value creation, institutional risk sharing, and tracking the effectiveness of the practice.

参考文献/References:

[1] Mestre-Ferrandiz J,Zozaya N,Alcalá B,et al.Multi-indication pricing:nice in theory but can it work in practice?[J].Pharmacoeconomics,2018,36(12)：1407-1420.
[2] 孙利华，范嘉宁.基于价值的多适应症药品医保准入模式探讨[J].中国医疗保险，2022（07）：53-56.
[3] Towse A,Cole A,Zamora B.The debate on indication-based pricing in the U.S.and five major European countries[R].London:Office of Health Economics,2018.
[4] 丁锦希，郝丽，陈烨，等.创新生物制品新增适应症医保支付标准调整机制研究[J].中国医疗保险，2020（03）：37-43.
[5] 代展菁，薛天祺，向贵圆，等.基于价值定价的多适应证药品医保支付国际经验及启示[J].中国药房，2021，32（02）：139-145.
[6] 李轶，丁锦希，李伟，等.多适应症药物准入支付标准测算模式研究[J].中国医疗保险，2021（10）：41-46.
[7] Garattini L,Curto A,van de Vooren K.Do the current performance-based schemes in Italy really work? "Success fee":a novel measure for cost-containment of drug expenditure[J].Value Health,2015,18(02):352.
[8] Navarria A,Drago V,Gozzo L,et al.Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure[J].Value Health,2015,18(01):131-136.
[9] Pearson S D,Dreitlein W B,Henshall C,et al.Indication-specific pricing of pharmaceuticals in the US healthcare system[J].J Comp Eff Res,2017,6(05):397-404.
[10] Pauwels K,Huys I,Vogler S,et al.Managed entry agreements for oncology drugs:lessons from the European experience to inform the future[J].Front Pharmacol,2017,4(08):171.
[11] Mills M,Kanavos P.Healthcare payer perspectives on the assessment and pricing of oncology multi-indication products:evidence from nine OECD Countries[J].PharmacoEconomics Open,2023,7:553-565.
[12] Pauwels K,Huys I,Casteels M,et,al.Industry perspectives on market access of innovative drugs: the relevance for oncology drugs[J].Front Pharmacol,2016,7:144.
[13] 张天问，张奥，郭思琦，等.创新药新增适应症的医保准入国际经验研究[J].中国医疗保险，2022（12）：116-121.
[14] Lawlor R,Wilsdon T,Darquennes E,et al.Accelerating patient access to oncology medicines with multiple indications in Europe[J].J Mark Access Health Policy,2021,9(01):1964791.
[15] F Verbeek,C van Gils, R Heine,et al.One size does not fit all: calculating the cost-effectiveness of multiple indications of pembrolizumab in the netherlands[J].Value in Health,2022,25(12):S9.
[16] Neri M,Towse A,Garau M.Multi-Indication Pricing(MIP): Practical solutions and steps to move forward[R].London:Office of Health Economics,2018.
[17] Cole A,Towse A,Lorgelly P,et al.Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals[R].Research Papers,2018.
[18] Víctor Preckler,MSc Jaime Espín.The role of indication-based pricing in future pricing and reimbursement policies:a systematic review[J].Systematic Literature Review,2022,25(04):666-675.
[19] Hans P.Binswanger and Vernon W.Ruttan.induced innovation. technology, institutions, and development [J].The Economic Journal,1979,89(354):437-439.
[20] 王樱澄，吴尧，杨岚，等.基于价值的多适应证药品医保准入与定价方法研究[J].中国药房，2023，34（02）：179-184. [21] 刘鹏，张伊静.中国式政策示范效果及其影响因素——基于两个示范城市建设案例的比较研究[J].行政论坛，2020，27（06）：65-73. [22] Wong J,Motulsky A,Abrahamowicz M,et al.Off-label indications for antidepressants in primary care:descriptive study of prescriptions from an indication based electronic prescribing system[J].BMJ,2017,356:j603. [23] Walker J L.The Diffusion of Innovations among the American States[J].The American Political Science Review,1969,63(03):880-899. [24] 韩晓睿.完整精算法与简易调算法——多适应症药物准入评估方法比较研究[J].中国医疗保险，2022（07）：9-14. [25] 王雯，谭婧，任燕，等.重新认识真实世界数据研究：更新与展望[J].中国循证医学志，2020，20（11）：1241-1246. [26] 印冠锦，张梦阳，吴惠庶，等.真实世界数据相关标准体系研究与应用进展[J].医学信息学杂志，2022，43（06）：30-35. [27] 丁伟.真实世界数据质量提升研究[D].沈阳药科大学，2022. [28] 李言生，韩士斌，苏明亮，等.医院真实世界数据治理平台建设探索[J].中国卫生信息管理杂志，2022，19（06）：925-930. [29] 徐国冲，翟文康.公共价值是如何被创造出来的?——兼评《创造公共价值：政府战略管理》与Recognizing Public Value[J].公共行政评论，2021（04）：179-188. [30] 张晓.医保支付的出发点是价值[J].中国医疗保险，2017（11）：32. [31] National Health Council.The patient voice in value:the National Health Council patient-centered value model rubric[EB/OL].(2023-02-13)[2023-11-17].https://nationalhealthcouncil.org/additional-resources/call-for-comments-patient-centered-value-model-rubric-and-get-ready-checklist-for-patient-organizations-2/. [32] Neumann P J,Garrison L P,Willke R J.The history and future of the “ISPOR Value Flower”:addressing limitations of conventional cost-effectiveness analysis[J].Value in Health,2022,25(04):558-565. [33] 崔鹏磊，李世勇，常峰，等.药品风险分担协议对中国大陆的启示——以澳大利亚、新西兰、中国台湾为例[J].中国卫生政策研究，2017，10（02）：21-26.

相似文献/References:

[1]毛心仪,姚峥嵘.制度创新理论视角下我国药品研发制度变迁设计[J].卫生经济研究,2021,38(7):38.
　MAO Xin-yi,YAO Zheng-rong.Institutional Change Design of Drug Research and Development in China from the Perspective of Institutional Innovation Theory[J].Journal Press of Health Economics Research,2021,38(06):38.

更新日期/Last Update: 2024-05-30